



**Investor News**  
No. 7/2014

## **Zealand to present at three healthcare conferences in September 2014**

*Copenhagen, 27 August 2014* – Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) informs that the company will present at the following three healthcare investor conferences in September 2014.

### **Goldman Sachs 1-on-1 Biotech Symposium, London (5 September)**

Zealand will present to and update investors during one-to-one meetings.

### **Bank of America Merrill Lynch Global Healthcare Conference, London (17-19 September)**

Zealand will make a group presentation on Wednesday 17 September at 11.25 BST (12.25 CET). In addition, the company will host one-to-one meetings on the same day.

### **Société Générale Healthcare and Biotechnology Conference, Paris (24 September)**

Zealand will present to and update investors during one-to-one and small group meetings.

In the presentations, Zealand’s management team will give an update on the status and outlook for the company’s portfolio of peptide therapeutics.

Please note that no new financial or other material new information relating to Zealand will be disclosed at the above listed conferences.

**\*\*\***

### **For further information, please contact:**

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications  
Tel: +45 5060 3689, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)



### **About Zealand Pharma**

Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and a mature portfolio of therapeutic products, which are all based on internal inventions. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead product is lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, marketed as Lyxumia<sup>®</sup> under a license agreement with Sanofi. Lyxumia<sup>®</sup> is approved in several countries globally, including Europe and Japan. In the US, submission of an NDA is expected in 2015, after completion of a cardiovascular outcome study, ELIXA. A once-daily single injection combination of Lyxumia<sup>®</sup> and Lantus<sup>®</sup> (LixiLan) is in Phase III development by Sanofi with planned first regulatory filing as early as at the end of 2015.

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has two collaborations with Boehringer Ingelheim in diabetes/obesity and cardio-metabolic diseases, one with Lilly in diabetes and obesity, one with Helsinn Healthcare in chemotherapy induced diarrhea and a license agreement with AbbVie in acute kidney injury.

For further information: [www.zealandpharma.com](http://www.zealandpharma.com)

Follow us on Twitter @ZealandPharma